药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Benzonatate
Rubella virus vaccine
The risk or severity of infection can be increased when Rubella virus vaccine is combined with Sunitinib.
Benzonatate
Pitolisant
The serum concentration of Sunitinib can be decreased when it is combined with Pitolisant.
Benzonatate
Delamanid
Sunitinib may increase the QTc-prolonging activities of Delamanid.
Benzonatate
Ertugliflozin
The therapeutic efficacy of Sunitinib can be increased when used in combination with Ertugliflozin.
Benzonatate
Vemurafenib
The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Vemurafenib.
Benzonatate
Moderna COVID-19 Vaccine
The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Sunitinib.
Benzonatate
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Sunitinib.
Benzonatate
Modified vaccinia ankara
The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Sunitinib.
Benzonatate
Varicella Zoster Vaccine (Recombinant)
The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Sunitinib.
Benzonatate
Yersinia pestis 195/p antigen (formaldehyde inactivated)
The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Sunitinib.
Benzonatate
Pertussis vaccine
The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Sunitinib.
Benzonatate
Smallpox (Vaccinia) Vaccine, Live
The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Sunitinib.
Benzonatate
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Sunitinib.
Benzonatate
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Sunitinib.
Benzonatate
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Sunitinib.
Benzonatate
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Sunitinib.
Benzonatate
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Sunitinib.
Benzonatate
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Sunitinib.
Benzonatate
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Sunitinib.
Benzonatate
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Sunitinib.